Clinical trials: Flow-mediated Vasodilatation (FMD)
Cardiovascular Disease
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension
The primary objective of the double-blind segment is to compare effects of alagebrium vs placebo on change from baseline in endothelial function, as assessed by flow-mediated vasodilation (FMD).
- Trial name
- NCT00302250
- Testing
- ALT-711 (alagebrium chloride)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Synvista Therapeutics, Inc
Cardiovascular Disease
STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH
Determine whether increasing arterial distensibility by decreasing advanced glycation end-product (AGE) cross-link components of vascular stiffness improves (a) endothelial-mediated vasoreactivity at rest, as assessed by…
- Trial name
- NCT00277875
- Testing
- ALT-711 (alagebrium chloride)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Synvista Therapeutics, Inc
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim